Tambe Moves Up To Lead Biocon Biologics
Replaces CEO Arun Chandavarkar, Who Will Continue To Serve As Director
Shreehas Tambe has been named as CEO of Biocon Biologics, taking over from Arun Chandavarkar, in the wake of the company’s milestone $3bn transaction for Viatris’s biosimilars business.
You may also be interested in...
As it continues to build on the biosimilars business gained from a major transaction with former partner Viatris, Biocon Biologics has announced a raft of executive appointments to bolster its management team.
With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.
Executive changes in 2022 reveal how the industry is adjusting to a volatile post-COVID environment.